Data Insights

Lemzoparlimab by AbbVie for Epithelial Ovarian Cancer: Likelihood of Approval

Lemzoparlimab is under clinical development by AbbVie and currently in Phase II for Epithelial Ovarian Cancer. According to GlobalData, Phase...

Data Insights

Lemzoparlimab by AbbVie for Marginal Zone B-cell Lymphoma: Likelihood of Approval

Lemzoparlimab is under clinical development by AbbVie and currently in Phase II for Marginal Zone B-cell Lymphoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Lemzoparlimab in Marginal Zone B-cell Lymphoma

Data Insights

Lemzoparlimab by AbbVie for Peritoneal Cancer: Likelihood of Approval

Lemzoparlimab is under clinical development by AbbVie and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Lemzoparlimab in Peritoneal Cancer

Data Insights

Lemzoparlimab by AbbVie for Non-Small Cell Lung Carcinoma: Likelihood of Approval

Lemzoparlimab is under clinical development by AbbVie and currently in Phase II for Non-Small Cell Lung Carcinoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Lemzoparlimab in Non-Small Cell Lung Carcinoma

Data Insights

Lemzoparlimab by AbbVie for Follicular Lymphoma: Likelihood of Approval

Lemzoparlimab is under clinical development by AbbVie and currently in Phase II for Follicular Lymphoma. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Lemzoparlimab in Follicular Lymphoma

Data Insights

Lemzoparlimab by AbbVie for Fallopian Tube Cancer: Likelihood of Approval

Lemzoparlimab is under clinical development by AbbVie and currently in Phase II for Fallopian Tube Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Lemzoparlimab in Fallopian Tube Cancer

Data Insights

Lemzoparlimab by AbbVie for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval

Lemzoparlimab is under clinical development by AbbVie and currently in Phase II for Primary Mediastinal B-Cell Lymphoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Lemzoparlimab in Primary Mediastinal B-Cell Lymphoma

Data Insights

Lemzoparlimab by AbbVie for Solid Tumor: Likelihood of Approval

Lemzoparlimab is under clinical development by AbbVie and currently in Phase II for Solid Tumor. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Lemzoparlimab in Solid Tumor

Data Insights

Lemzoparlimab by AbbVie for Diffuse Large B-Cell Lymphoma: Likelihood of Approval

Lemzoparlimab is under clinical development by AbbVie and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Lemzoparlimab in Diffuse Large B-Cell Lymphoma

Data Insights

Risk adjusted net present value: What is the current valuation of I-Mab's Lemzoparlimab?

Lemzoparlimab is a monoclonal antibody commercialized by I-Mab, with a leading Phase II program in Primary Mediastinal B-Cell Lymphoma. According...

Net Present Value Model: I-Mab's Lemzoparlimab